B. Jansik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
B. Jansik has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ada Böhm
IT4Innovations, VSB-TU Ostrava, Ostrava, Czech Republic
2 shared publications - Andrea Rosario Beccari
EXSCALATE, Dompé farmaceutici S.p.A.
2 shared publications - Andrew Emerson
HPC Department
2 shared publications - Biagio Cosenza
University of Salerno, Fisciano (Salerno), Italy
2 shared publications - Bruno Guindani
Politecnico di Milano
2 shared publications - Carmine Talarico
Dompé farmaceutici S.p.A
2 shared publications
Latest Publications
- Open Access
- 7 May 2024
- Published by Association for Computing Machinery (ACM)
- p. 107-109
LIGATE - LIgand Generator and portable drug discovery platform AT Exascale
The COVID-19 pandemic demonstrates that a top priority for society, now and in the future, is to be able to respond quickly to diseases with effective treatments. Among the new tools that pharmaceutical industries and researchers have in their hands nowadays, there are the extensive computer simulations capable of evaluating in-silico the interaction between possible drugs and the target proteins. The central goal of the LIGATE project is to create and validate a leading application solution for drug discovery in High-Performance Computing (HPC) systems up to the exascale level. The overall project purpose is the automation of the drug design process, which is currently performed with substantial human effort throughout the different phases of the process: preparation of input parameters, management of data sets with billions of molecules, interaction with HPC queue management systems to handle jobs, and optimization of scoring function parameters and thresholds.
- 7 May 2024
- Published by Association for Computing Machinery (ACM)
- p. 107-109
Open AccessLIGATE - LIgand Generator and portable drug discovery platform AT Exascale
The COVID-19 pandemic demonstrates that a top priority for society, now and in the future, is to be able to respond quickly to diseases with effective treatments. Among the new tools that pharmaceutical industries and researchers have in their hands nowadays, there are the extensive computer simulations capable of evaluating in-silico the interaction between possible drugs and the target proteins. The central goal of the LIGATE project is to create and validate a leading application solution for drug discovery in High-Performance Computing (HPC) systems up to the exascale level. The overall project purpose is the automation of the drug design process, which is currently performed with substantial human effort throughout the different phases of the process: preparation of input parameters, management of data sets with billions of molecules, interaction with HPC queue management systems to handle jobs, and optimization of scoring function parameters and thresholds.
- Open Access
- 9 May 2023
- Published by Association for Computing Machinery (ACM)
- p. 272-278
Tunable and Portable Extreme-Scale Drug Discovery Platform at Exascale
Today digital revolution is having a dramatic impact on the pharmaceutical industry and the entire healthcare system. The implementation of machine learning, extreme-scale computer simulations, and big data analytics in the drug design and development process offers an excellent opportunity to lower the risk of investment and reduce the time to the patient. Within the LIGATE project 1, we aim to integrate, extend, and co-design best-in-class European components to design Computer-Aided Drug Design (CADD) solutions exploiting today's high-end supercomputers and tomorrow's Exascale resources, fostering European competitiveness in the field. The proposed LIGATE solution is a fully integrated workflow that enables to deliver the result of a virtual screening campaign for drug discovery with the highest speed along with the highest accuracy. The full automation of the solution and the possibility to run it on multiple supercomputing centers at once permit to run an extreme scale in silico drug discovery campaign in few days to respond promptly for example to a worldwide pandemic crisis.
- 9 May 2023
- Published by Association for Computing Machinery (ACM)
- p. 272-278
Open AccessTunable and Portable Extreme-Scale Drug Discovery Platform at Exascale
Today digital revolution is having a dramatic impact on the pharmaceutical industry and the entire healthcare system. The implementation of machine learning, extreme-scale computer simulations, and big data analytics in the drug design and development process offers an excellent opportunity to lower the risk of investment and reduce the time to the patient. Within the LIGATE project 1, we aim to integrate, extend, and co-design best-in-class European components to design Computer-Aided Drug Design (CADD) solutions exploiting today's high-end supercomputers and tomorrow's Exascale resources, fostering European competitiveness in the field. The proposed LIGATE solution is a fully integrated workflow that enables to deliver the result of a virtual screening campaign for drug discovery with the highest speed along with the highest accuracy. The full automation of the solution and the possibility to run it on multiple supercomputing centers at once permit to run an extreme scale in silico drug discovery campaign in few days to respond promptly for example to a worldwide pandemic crisis.